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MaBACKGROUND Older patients with severe aortic stenosis (AS) are increasingly identified as having cardiac amyloidosis
(CA). It is unknown whether concomitant AS-CA has worse outcomes or results in futility of transcatheter aortic valve
replacement (TAVR).
OBJECTIVES This study identified clinical characteristics and outcomes of AS-CA compared with lone AS.
METHODS Patients who were referred for TAVR at 3 international sites underwent blinded research core laboratory
99mtechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) bone scintigraphy (Perugini grade 0: negative; grades 1
to 3: increasingly positive) before intervention. Transthyretin-CA (ATTR) was diagnosed by DPD and absence of a clonal
immunoglobulin, and light-chain CA (AL) was diagnosed via tissue biopsy. National registries captured all-cause mortality.
RESULTS A total of 407 patients (age 83.4  6.5 years; 49.8% men) were recruited. DPD was positive in 48 patients
(11.8%; grade 1: 3.9% [n ¼ 16]; grade 2/3: 7.9% [n ¼ 32]). AL was diagnosed in 1 patient with grade 1. Patients with grade
2/3 had worse functional capacity, biomarkers (N-terminal pro-brain natriuretic peptide and/or high-sensitivity troponin
T), and biventricular remodeling. A clinical score (RAISE) that used left ventricular remodeling (hypertrophy/diastolic
dysfunction), age, injury (high-sensitivity troponin T), systemic involvement, and electrical abnormalities (right bundle
branch block/low voltages) was developed to predict the presence of AS-CA (area under the curve: 0.86; 95% confidence
interval: 0.78 to 0.94; p < 0.001). Decisions by the heart team (DPD-blinded) resulted in TAVR (333 [81.6%]), surgical
AVR (10 [2.5%]), or medical management (65 [15.9%]). After a median of 1.7 years, 23% of patients died. One-year
mortality was worse in all patients with AS-CA (grade: 1 to 3) than those with lone AS (24.5% vs. 13.9%; p ¼ 0.05). TAVR
improved survival versus medical management; AS-CA survival post-TAVR did not differ from lone AS (p ¼ 0.36).
CONCLUSIONS Concomitant pathology of AS-CA is common in older patients with AS and can be predicted clinically.
AS-CA has worse clinical presentation and a trend toward worse prognosis, unless treated. Therefore, TAVR should not
be withheld in AS-CA. (J Am Coll Cardiol 2021;77:128–39) © 2021 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2020.11.006
m the aDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria; bInstitute of
rdiovascular Science, University College London, London, United Kingdom; cCardiology Department, Guy’s and St. Thomas’
S Foundation Trust, London, United Kingdom; dBarts Heart Centre, St. Bartholomew’s Hospital, London, United Kingdom;
epartment of Nuclear Medicine, Medical University of Vienna, Vienna, Austria; fJohn Radcliffe Hospital, Oxford, United
gdom; gQueen Mary University London, London, United Kingdom; hNational Amyloid Centre, London, United Kingdom; and
iUCL/ULCH NIHR Biomedical Research Centre, London, United Kingdom.
e authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’
titutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information,
it the Author Center.
nuscript received August 11, 2020; revised manuscript received October 26, 2020, accepted November 4, 2020.
J A C C V O L . 7 7 , N O . 2 , 2 0 2 1 Nitsche et al.
J A N U A R Y 1 9 , 2 0 2 1 : 1 2 8 – 3 9 Outcome of Cardiac Amyloidosis and Aortic Stenosis
129AB BR E V I A T I O N S
AND ACRONYM S
AL = immunoglobulin light-
chain cardiac amyloidosis
AS = aortic stenosis




AUC = area under the curve
CA = cardiac amyloidosis




HR = hazard ratio
hsTnT = high-sensitivity
troponin T
IQR = interquartile range
LS = longitudinal strain
LV = left ventricular




OR = odds ratio
RAISE = remodeling, age,
injury, system, and electrical
SAVR = surgical aortic valve
replacement
SV = stroke volumeD egenerative aortic stenosis (AS) affects >3%of people aged 75 years or older (1). In se-vere AS with symptoms or cardiac decom-
pensation, surgical aortic valve replacement (SAVR)
or transcatheter-based aortic valve replacement
(TAVR) are indicated to improve outcome (2).
Morphologically, significant AS is characterized by
hypertrophic myocardial remodeling, similar to car-
diac amyloidosis (CA). CA is an infiltrative process
caused by myocardial deposition of amyloid fibrils.
The 2 major amyloid proteins found in ventricular
myocardium are transthyretin (TTR), which predomi-
nantly affects older adults, and immunoglobulin light-
chain (AL), which occurs less frequently (3). The coex-
istence of AS and CA in patients referred for TAVR
ranges from 9% to 16% (4–7). Increased diagnosis
of CA is driven by the sensitivity and specificity of
bone scintigraphy (99mtechnetium-3,3-diphosphono-
1,2-propanodicarboxylic acid [DPD], 99mtechnetium-
pyrophosphate, or 99mtechnetium-hydroxymethylene
diphosphonate), in particular for ATTR. This is
important because of the advent of novel CA therapies
(8). The survival implications of concurrent AS-CA
remain unclear. Three potentially underpowered
studies recently reported no mortality difference of
AS-CA compared with lone AS in cohorts of approxi-
mately 200 patients (4,6,9). Therefore, the present
multicenter study was designed to evaluate the
differential mortality hazard of AS-CA versus lone AS,
as well as predictors of AS-CA beyond the existing
diagnostic criteria.SEE PAGE 140
TAVR = transcatheter aortic
valve replacementMETHODS
STUDY POPULATION. This prospective, multicenter
study enrolled consecutive adult patients with severe
degenerative AS who were referred for TAVR at 3
tertiary referral centers: Barts Heart Centre, London,
United Kingdom (October 2016 to January 2019); John
Radcliffe Hospital, Oxford, United Kingdom (January
2018 to June 2019); and Vienna General Hospital,
Vienna, Austria (October 2017 to February 2019). This
study included patients from 2 previous published
studies (4,6), which expanded the study cohort,
follow-up, and implementation of the blinded core
laboratory analysis of bone scintigraphy.
To reduce selection bias, recruitment took place
after referral to AVR and before discussion by the
heart team. Therefore, we anticipated some crossover
to medical therapy and to surgical valve replacement.
All patients underwent blinded DPD bone scintig-
raphy, as well as clinical and laboratory assessment, a6-min walk test, electrocardiography, and
transthoracic echocardiography with strain
analysis. All-cause mortality was selected as
the primary study endpoint, was determined
using national data via the U.K. National
Health Service (NHS Spine), and Austrian
Death Registry, and was 100% complete. Peri-
procedural complications were defined using
the Valve Academic Research Consortium-2
criteria. This study complied with the Decla-
ration of Helsinki; relevant local ethics and
site approvals were obtained, and all patients
provided written informed consent.
LABORATORY AND ELECTROCARDIOGRAPHIC
ASSESSMENT. For detection of pathological
light-chains underlying AL-CA, laboratory
testing included serum immunoglobins and
free light-chain quantification, as well as
serum and/or urine immunofixation, which
was performed in all DPD-positive patients.
In addition, N-terminal probrain natriuretic
peptide (NT-proBNP) and high-sensitivity
troponin T (hs-TnT) serum levels were
determined in all patients. Electrocardio-
grams were recorded according to current
recommendations (10). Voltage/mass ratio
was determined in patients without bundle
branch block, and paced rhythm was assessed
by dividing the Sokolow-Lyon index by the
left ventricular (LV) mass index on echocar-
diography. The Sokolow-Lyon index was
calculated as the sum of pre-cordial voltage
(S-wave in lead V1 plus R-wave in lead V5 or
V6 [SV1 þ RV5 or V6]). Low-limb lead voltages were
defined as all limb leads with an ampli-
tude of #0.5 mV.
ECHOCARDIOGRAPHY. All patients underwent clin-
ical transthoracic echocardiography, primarily for
assessment of AS severity, any concomitant valve
pathology, and ventricular function according to the
local protocols written in accordance with interna-
tional imaging guidelines (11–14). LV ejection fraction
(LVEF) was calculated using Simpson’s biplane test
where possible or otherwise quantified visually.
Stroke volume (SV) was quantified using the LV
outflow tract velocitytime integral and the LV
outflow tract diameter and then indexed to body
surface area. LV mass was calculated using the for-
mula from Devereux et al. (15). Strain analysis was
performed in the 4-, 3-, and 2-chamber apical views.
Regional longitudinal strain (LS) was determined in
the 17 segments of the LV (16). Global LS was calcu-
lated as the average LS of these 17 segments. Relative
FIGURE 1 Patient Population
Consecutive AS patients in evaluation for
TAVR at 3 centers (N = 407):
- Vienna (N = 207)
- London (N = 170)
- Oxford (N = 30)
99mTc-DPD bone scintigraphy (N = 407)
Aortic valve replacement
(N = 342):
- TAVR (N = 332)
- SAVR (N = 10)
Medical management
(N = 65)
Follow-up after DPD scan: 700 ± 292 days
Patient population. AS ¼ aortic stenosis; DPD ¼ 99mtechnetium-3,3-diphosphono-1,2-
propanodicarboxylic acid; SAVR ¼ surgical aortic valve replacement;
TAVR ¼ transcatheter aortic valve replacement.
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130apical LS was calculated as average apical LS/(average
basal LS þ average mid-LS). The myocardial contrac-
tion fraction, which indexes SV to the myocardial
volume, was calculated as previously described (17).
The classic low-flow, low gradient was defined as an
aortic valve area of #1.0 cm2, with an LVEF of <50%,
an indexed SV of <35 ml/m2, a peak aortic valve ve-
locity of <4 m/s, and a mean gradient of <40 mm Hg.
In contrast, the paradoxical low-flow, low-gradient
was defined as an LVEF of $50% but an indexed SV
of <35 ml/m2, peak velocity of <4 m/s, and a mean
gradient of <40 mm Hg (14). When equivocal, AS
severity was adjudicated using low-dose dobutamine
stress echocardiography and the computed
tomographyderived aortic valve calcium score.
DPD BONE SCINTIGRAPHY. Blinded, pre-TAVR DPD
bone scintigraphy was performed in all patients, who
were scanned using Phillips Brightview single-photon
emission computed tomographycomputed tomog-
raphy gamma camera (Philips Healthcare, Amster-
dam, the Netherlands), Siemens Symbia gamma
camera (Siemens Healthcare, Erlangen, Germany),
and/or Pulse CDC gamma camera (IS2, London,
United Kingdom), or the General Electric Infinia
Hawkeye 4/GE Discovery 670 hybrid gamma camera
(Vienna, Austria) following the administration of 700
MBq of DPD. Whole body images were acquired at ascan speed of 10 cm/min using low-energy, high-res-
olution collimators (18). Planar whole body images
were performed 3 h after tracer administration at all
study sites. Additional single-photon emission
computed tomographycomputed tomography of the
chest at 3 h was performed in London and/or Oxford.
BLINDING PRE-PROCEDURE. DPD scans were re-
ported blinded to the clinical data by 2 readers from
each institution (C.N., T.V., P.S., L.M.) according to
the Perugini classification (19), where grade 0 repre-
sented no cardiac uptake with normal bone uptake
(i.e., negative) and grades 1 to 3 represented
increasing cardiac uptake with increasing bone
attenuation and soft tissue uptake. In discrepant
cases (adjudication different to the previous local
DPD grade; n ¼ 5), which occurred more often in
borderline cases who did not undergo single-photon
emission computed tomography, the adjudication
panel (C.N., T.V., P.S., L.M., T.A.T.) re-reviewed the
scans and assigned the final diagnosis by consensus.
DIAGNOSIS OF CA. Referring to the different disease
burden in Perugini grade 1 (subclinical amyloid
deposition) versus Perugini grade $2 (clinical
amyloidosis), these 2 conditions were defined as AS-
amyloid versus AS-amyloidosis, respectively. The
presence of ATTR was diagnosed in patients with
cardiac tracer uptake on bone scintigraphy and un-
remarkable serum- and urine-free light-chain assess-
ment (8). AL was diagnosed if these were elevated
and there was endomyocardial or extracardiac biopsy
amyloid of light-chain origin. AL amyloidosis was
considered possible in 3 cases (2 in grade 1 and 1 in
grade 2). In the first patient in grade 1, endomyo-
cardial biopsy confirmed ATTR; the second patient in
grade 1 died shortly after TAVR with an autopsy
diagnosis of AL (AL-kappa positive, TTR negative).
The patient in grade 2 had a monoclonal gammopathy
of undetermined significance with an inconclusive
bone marrow biopsy; this patient declined further
biopsy. However, because of the known coexistence
of ATTR and monoclonal protein without cardiac AL
amyloidosis (8) and the low percentage of AL with
Perugini uptake $2 (18), this patient was classified
as ATTR.
STATISTICAL ANALYSIS. All statistical analyses were
computed using SPSS version 26 (IBM, Armonk, New
York). Continuous data are expressed as mean  SD or
as median (interquartile range [IQR]), and categorical
variables are presented as numbers and percentages.
Differences between groups were analyzed with the
chi-square and Kruskal Wallis tests, as appropriate.
Post hoc analyses were performed using Dunn-
Bonferroni tests for continuous variables. The
TABLE 1 Baseline Clinical Characteristics
DPD 0 (n ¼ 359; 88.2%) DPD 1 (n ¼ 16; 3.9%) DPD 2/3 (n ¼ 32; 7.9%) p Value
Age, yrs 83.6 (72.387.6) 85.4 (80.289.1) 86.6 (84.191.8)* 0.001
Male 48.2 50.0 65.6 0.167
BMI, kg/m2 26.4 (23.529.7) 27.6 (24.530.0) 25.7 (23.229.1) 0.429
EuroSCORE II 4.2 (3.75.1) 4.1 (3.64.6) 4.5 (3.95.2) 0.297
Systolic BP, mm Hg 134 (120148) 138 (118162) 126 (110150) 0.319
Diastolic BP, mm Hg 69 (6079) 80 (5891) 68 (6074) 0.244
Arterial hypertension 83.4 62.5†‡ 90.6 0.046
Pre-interventional PM 14.6 6.3 25.0 0.173
Diabetes 26.1 18.8 18.8 0.550
Atrial fibrillation 36.3 50.0 50.0 0.186
CAD 45.9 68.8 21.9*‡ 0.005
Previous MI 10.3 12.5 6.3 0.724
Previous PCI 22.8 37.5 3.1*‡ 0.011
PAD 11.5 0.0 0.0* 0.046
Cerebral OD 16.4 0.0 12.5 0.202
CTS 1.1 20.0† 18.8* <0.001
AS phenotype 0.176
D1: high gradient 67.2 53.3 43.8
D2: LFLG, LVEF $50% 16.4 26.7 28.1
D3: LFLG, LVEF <50% 16.4 20.0 28.1
Asymptomatic 7.7 6.7 6.3 0.948
Dyspnea 84.3 86.7 90.6 0.620
Angina 25.6 13.3 18.8 0.407
Syncope 19.1 6.7 12.5 0.324
Hs-TnT, ng/l 24 (1539) 25 (2332) 49 (3387)*‡ <0.001
NT-proBNP, pg/ml 1,606 (6403,843) 1,632 (9333,619) 4,855 (1,4127,494)* 0.003
Creatinine, mg/dl 1.1 (0.91.4) 1.3 (1.11.4) 1.1 (0.91.3) 0.230
eGFR, ml/min/1.73 m2 62.3 (46.477.9 52.5 (39.958.3) 61.4 (45.273.7) 0.213
Hemoglobin, mg/dl 11.9 (10.413.0) 13.3 (11.714.0) 11.8 (10.813.0) 0.097
Albumin, g/l 40.4 (32.640.0) 42.1 (41.944.5) 39.0 (35.642.0) 0.132
6-MWT, m 194 (82286) 260 (191369) 94 (50225)*‡ 0.034
Values are median (interquartile range) or %. *DPD grade 2/3 versus DPD grade 0: p # 0.05. †DPD grade 1 versus DPD grade 0: p # 0.05. ‡DPD grade 2/3 versus DPD grade 1:
p # 0.05.
6-MWT ¼6-min walk test; BMI ¼ body mass index; BP ¼ blood pressure; CAD ¼ coronary artery disease; CTS ¼ carpal tunnel syndrome; DPD ¼ 99mtechnetium-labeled 3,3-
diphosphono-1,2-propanodicarboxylic acid bone scintigraphy; eGFR ¼ estimated glomerular filtration rate; EuroSCORE II ¼ European System for Cardiac Operative Risk
Evaluation II; LFLG ¼ low-flow, low-gradient; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NT-proBNP ¼ N-terminal prohormone of brain natriuretic
peptide; OD ¼ occlusive disease; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; PM ¼ pacemaker.
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131discriminative power of the novel scoring system was
established using the receiver-operating character-
istic curve analysis with area under the curve (AUC)
and respective 95% confidence intervals (CIs). Uni-
variate and multivariate Cox regression analyses were
performed for the overall and AVR cohort to evaluate
predictors of mortality (Supplemental Tables 1 to 3).
All baseline parameters were proposed for univariate
analysis. Multivariate analysis was performed using a
stepwise forward selection, with the univariate cutoff
p value of #0.05 used to enter the multivariate model
for univariate testing and the p value of >0.1 used for
removal from multivariate testing. To allow better
comparison between continuous parameters within
the multivariate model, scaled hazard ratios (HRs) (Z-
scores) were created by subtracting the mean from
individual values and dividing them by the respectiveSD. The proportional hazards assumption was tested
with examination of Schoenfeld residuals. Kaplan-
Meier curves were used to evaluate the prognostic
significance of CA and AVR. Univariate and multi-
variate binary logistic analyses were applied to eval-
uate the association of parameters with the presence
of CA. A p value #0.05 was considered statisti-
cally significant.
RESULTS
PATIENT CHARACTERISTICS. A total of 407 patients
referred for TAVR (mean age: 83.4  6.5 years; 49.8%
men) were recruited in 3 centers (Figure 1). All pa-
tients underwent DPD bone scintigraphy performed
16 days (IQR: 2 to 50 days) before AVR. Treatment
decisions were determined by the multidisciplinary
TABLE 2 Baseline Echocardiographic and Electrocardiographic Characteristics
DPD 0 (n ¼ 359; 88.2%) DPD 1 (n ¼ 16; 3.9%) DPD 2/3 (n ¼ 32; 7.9%) p Value
Baseline echocardiographic parameters
LVEDD, mm 45.0 (40.0 to 50.0) 44.0 (39.0 to 50.0) 43.0 (38.0 to 49.0) 0.308
RVEDD, mm 36.0 (31.0 to 41.0) 36.0 (32.0 to 44.0) 38.0 (33.0 to 43.0) 0.158
IVS, mm 14.0 (12.0 to 16.0) 13.0 (12.0 to 14.0) 16.0 (14.0 to 19.0)*† 0.012
LA diameter, mm 51.0 (41.0 to 62.0) 55.0 (42.0 to 64.0) 56.0 (44.0 to 66.0) 0.405
AVA, cm2 0.7 (0.6 to 0.8) 0.7 (0.6 to 0.8) 0.7 (0.5 to 0.9) 0.814
AV Vmax, m/s 4.2 (3.9 to 4.6) 4.0 (3.4 to 4.7) 3.9 (3.2 to 4.6)* 0.017
AV-PPG, mm Hg 71.0 (60.0 to 84.0) 64.0 (45.0 to 87.0) 60.0 (42.0 to 86.0)* 0.018
AV-MPG, mm Hg 44.0 (35.0 to 53.0) 39.0 (27.0 to 49.0) 36.0 (25.0 to 48.0)* 0.017
SVi, ml/m2 40.1 (31.4 to 48.0) 33.2 (30.0 to 39.1)‡ 35.8 (27.4 to 44.0) 0.021
LVEF, % 58.0 (44.0 to 64.0) 55.0 (35.0 to 61.0) 51.0 (42.0 to 64.0) 0.371
LVEDV, ml 91.0 (68.0 to 117.0) 87.0 (77.0 to 107.0) 80.0 (61.0 to 99.0) 0.201
LVESV, ml 34.0 (22.0 to 51.0) 33.0 (24.0 to 65.0) 36.0 (22.0 to 43.0) 0.819
Peak TR velocity, m/s 3.0 (2.4 to 3.5) 3.2 (2.0 to 3.8) 3.4 (2.6 to 4.1) 0.074
sPAP, mm Hg 39.0 (27.0 to 50.0) 48.0 (18.0 to 53.0) 49.0 (32.0 to 61.0) 0.062
E-wave deceleration time, ms 217 (166 to 281) 229 (189 to 337) 196 (158 to 246) 0.143
E/A ratio§ 0.80 (0.68 to 1.20) 1.35 (0.64 to 3.09) 1.43 (0.88 to 2.43)* 0.010
TAPSE, mm 2.1 (1.6 to 2.5) 2.1 (1.6 to 2.2) 1.8 (1.3 to 2.3) 0.073
LV mass index, g/m2 127 (101 to 151) 120 (91 to 163) 150 (119 to 177)*† 0.017
MCF, % 33.6 (25.4 to 45.1) 34.8 (20.5 to 40.7) 24.5 (20.6 to 29.3)* 0.001
GLS, % 15.6 (19.3 to 10.2) 12.2 (18.0 to 8.6) 13.7 (17.3 to 10.2) 0.433
Apical LS, % 21.0 (26.6 to 13.2) 19.8 (26.1 to 5.8) 21.5 (25.2 to 16.0) 0.881
Midventricular LS, % 13.3 (17.5 to 8.8) 10.2 (18.7 to 7.2) 10.1 (13.8 to 7.3) 0.214
Basal LS, % 10.6 (13.6 to 6.5) 9.3 (12.0 to 5.6) 7.4 (10.8 to 3.0) 0.072
Apical/(mid þ basal) 0.84 (0.69 to 1.05) 0.87 (0.55 to 1.61) 1.10 (0.85 to 1.78)* 0.005
ECG parameters
Heart rate, beats/min 70 (62 to 79) 74 (68 to 83) 68 (60 to 77) 0.355
Sokolow-Lyon index, mV 2.25 (1.70 to 2.95) 1.25 (1.03 to 1.96)* 1.68 (1.33 to 2.35)* <0.001
VMR, mV/g/m2  10-2 1.84 (1.29 to 2.79) 1.18 (0.66 to 2.02)* 1.06 (0.83 to 1.85)* <0.001
Low voltage limb 3.2 0.0 3.1 0.783
QRS duration, ms 96 (86 to 118) 128 (106 to 141)‡ 107 (90 to 135) 0.005
LBBB 8.7 0.0 3.1 0.259
RBBB 8.7 33.3‡ 18.8 0.003
Values are median (interquartile range) or %. *DPD grade 2/3 versus DPD grade 0: p # 0.05. †DPD grade 2/3 versus DPD grade 1: p#0.05. ‡DPD grade 1 versus DPD grade 0:
p # 0.05. §For patients in sinus rhythm at the time of echocardiography.
AV ¼ aortic valve; AVA ¼ aortic valve area; EDD ¼ end-diastolic diameter; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end-systolic volume; GLS ¼ global
longitudinal strain; IVS ¼ interventricular septum; LA ¼ left atrial; LBBB ¼ left bundle branch block; LS ¼ longitudinal strain; LV ¼ left ventricular; MCF ¼ myocardial
contraction fraction; MPG¼mean pressure gradient; PPG ¼ peak pressure gradient; RBBB ¼ right bundle branch block; RV¼ right ventricular; sPAP¼ systolic pulmonary artery
pressure; SVi ¼ stroke volume index; TAPSE ¼ tricuspid annular plane systolic excursion; TR ¼ tricuspid regurgitation; Vmax ¼ peak velocity; VMR ¼ voltage/mass ratio; other
abbreviation as in Tale 1.
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132heart team. Of these 407 patients, 333 (81.6%) un-
derwent TAVR; SAVR was performed in 10 (2.5%)
patients, and conservative management or ongoing
surveillance was pursued in 65 (15.9%) patients.
PREVALENCE, TYPE, AND PREDICTORS OF AS-CA.
Cardiac tracer uptake on DPD bone scintigraphy was
present in 48 patients (11.8%). Distribution according
to the Perugini classification was as follows: 16 (3.9%)
patients were in grade 1 (AS-amyloid), and 32 (7.9%)
patients were in grade 2/3 (AS-amyloidosis). ATTR
was found in 47 patients (all wild-type confirmed by
genotyping), and 1 patient had AL, as previ-
ously described.Independent predictors of presence of CA by
multivariate linear regression analysis were a longer
QRS duration (odds ratio [OR]: 2.51; 95% CI: 1.15 to
5.49; p ¼ 0.021), a lower voltage/mass ratio (OR: 0.37;
95% CI: 0.16 to 0.87; p ¼ 0.022), and history of carpal
tunnel syndrome (OR: 1.55; 95% CI: 1.06 to 2.28;
p ¼ 0.024).
LONE AS VERSUS AS-AMYLOIDOSIS (GRADE 2/3
AS-CA). Patients with AS-amyloidosis (grade 2/3 AS-
CA; n ¼ 32) were 3 years older compared with pa-
tients with lone AS (86.6 vs. 83.6 years; p < 0.001),
with a trend toward higher percentage in men (men:
65% vs. women: 48%; p¼ 0.06) (Table 1); patients with
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Scoring system for the discrimination of lone AS and dual pathology AS-CA. AFib ¼ atrial fibrillation; AS ¼ aortic stenosis; AUC ¼ area under
the curve; BBB ¼ bundle branch block; CA ¼ cardiac amyloidosis; CTS ¼ carpal tunnel syndrome; Hs-TnT ¼ high-sensitivity troponin T; IVS ¼
interventricular septum; PM ¼ pacemaker; RBBB ¼ right bundle branch block; SR ¼ sinus rhythm.
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133AS-amyloidosis had a higher prevalence of carpal
tunnel syndrome (18.8% vs. 1.1%; p < 0.001) and had a
lower prevalence of coronary and peripheral artery
disease (p < 0.05). Functional capacity was decreased
significantly, as measured by a shorter 6-min walk
distance (94 m [IQR: 50 to 225 m] vs. 194 m [IQR: 82 to
286 m]; p ¼ 0.038). Cardiac biomarkers were signifi-
cantly elevated: NT-proBNP: 4,855 ng/dl (IQR: 1,412 to
7,494 ng/dl) versus 1,606 ng/dl (IQR 640 to 3,843 ng/
dl) in lone AS (p ¼ 0.001); and hsTnT: 49 ng/l (IQR: 33
to 87 ng/l) versus 24 ng/l (IQR: 15 to 39 ng/l) (p < 0.001;
normal hsTnT: <14 ng/l).
AS-amyloidosis was characterized by a lower
Sokolow-Lyon voltage (1.7 mV [IQR: 1.3 to 2.4 mV] vs.
2.3 mV [IQR: 1.7 to 3.0 mV]; p ¼ 0.007) and
voltage/mass ratio (1.1 mV/g/m2  102 [IQR: 0.8 to
1.9 mV/g/m2  102] vs. 1.8 mV/g/m2  102 [IQR: 1.3
to 2.8 mV/g/m2  102]; p ¼ 0.001). Higher right
bundle branch block prevalence did not reach
significance (18.8% vs. 8.7%; p ¼ 0.06).On echocardiographic assessment (Table 2), pa-
tients with AS-amyloidosis had slightly lower gradi-
ents (aortic valve Vmax 3.9 m/s vs. 4.2 m/s; aortic
valve peak/mean gradient 60/36 mm Hg vs.
71/44 mm Hg; p < 0.05), although there was no
significant difference in absolute or indexed aortic
valve area (p ¼ 0.5 and p ¼ 0.3, respectively). Low-
flow, low-gradient AS (stage D2 or D3) was more
prevalent among patients with AS-amyloidosis (56.2%
vs. 32.9%; p ¼ 0.01) and was equally split between
classical and paradoxical low-flow, low-gradient AS.
Moreover, patients with AS-amyloidosis exhibited
worse cardiac remodeling with greater LV hypertro-
phy (LV mass index: 150 g/m2 [IQR: 119 to 177 g/m2]
vs. 127 g/m2 [IQR: 101 to 151 g/m2]; p ¼ 0.006) and
worse diastolic dysfunction. LVEFs were not different
(p ¼ 0.39), whereas indexed SV trended to be lower
(35.8 ml/m2 [IQR: 27.4 to 44.0 ml/m2] vs. 40.1 ml/m2
[IQR: 31.4 to 48.0 ml/m2]; p ¼ 0.06). The myocardial
contraction fraction, the SV per myocardial volume,






















Patients with AS-CA experienced a trend toward higher all-cause mortality at 1 year in all patients referred for aortic valve replacement.
Abbreviations as in Figure 2.
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134was significantly worse (24.5% [IQR: 20.6% to 29.3%]
vs. 33.6% [IQR: 25.4% to 45.1%]; p < 0.001). Global LS
was not different (13.7 [IQR: 17.3 to 10.2] vs. 15.6
[IQR: 19.3 to 10.2]; p ¼ 0.3), but relative apical
sparing was more pronounced in AS-amyloidosis (1.1
[IQR: 0.9 to 1.8] vs. 0.8 [IQR: 0.7 to 1.1]; p < 0.01).
LONE AS VERSUS AS-AMYLOID (GRADE 1 AS-CA).
Among patients with AS-amyloid (grade 1 AS-CA;
n ¼ 16), cardiovascular risk profiles were comparable
with lone AS, except for a lower prevalence of arterial
hypertension. Carpal tunnel syndrome was more
common (20.0% vs. 1.1%; p < 0.001). Cardiac markers
were the same. With the exception of a lower SV index
in patients with AS-amyloid (33 ml/m2 [IQR: 30 to 39
ml/m2] vs. 40 ml/m2 [IQR: 31 to 48 ml/m2]; p ¼ 0.033),
echocardiographic parameters did not differ,
including LV mass index, LVEF, myocardial contrac-
tion fraction, E/A ratio, and strain values. On electro-
cardiography, patients with AS-amyloid displayed
longer QRS duration, mainly due to a higher preva-
lence of right bundle branch block (33.3% vs. 8.7%;
p ¼ 0.002), and a lower Sokolow-Lyon voltage (1.3 mV
[IQR: 1.0 to 2.0 mV] vs. 2.3 mV [IQR: 1.7 to 3.0 mV];
p ¼ 0.002) and voltage/mass ratio (1.2 mV/g/m2  102
[IQR: 0.7 to 2.0 mV/g/m2  102] vs. 1.8 mV/g/m2 102
[IQR: 1.3 to 2.8 mV/g/m2  102]; p ¼ 0.02).REMODELING, AGE, INJURY, SYSTEM, AND ELECTRICAL
SCORING SYSTEM FOR DISCRIMINATION OF LONE AS
VERSUS AS-CA. To aid clinical AS-amyloid and/or AS-
amyloidosis detection, a scoring system was created
across 5 domains: remodeling (LV hypertrophy
and/or diastolic dysfunction), age, injury (hsTnT),
systemic (carpel tunnel syndrome), and electrical
(right bundle branch block or low voltages) (RAISE).
The RAISE score captures systemic disease (carpal
tunnel syndrome, 3 points), disproportionate elec-
trical remodeling (right bundle branch block, 2
points; low voltages or Sokolow-Lyon index <1.9 mV,
1 point), disproportionate myocardial remodeling
(marked LV hypertrophy; septal wall thickness
$18 mm, 1 point; marked diastolic dysfunction, E/A
ratio >1.4, 1 point), chronic myocardial injury (hsTnT
>20 ng/l, 1 point), and age (85 years or older, 1 point).
The score was derived in the Vienna cohort with
strong discriminative power for the distinction of
lone AS and AS-CA (AUC: 0.86; 95% CI: 0.78 to
0.94; p < 0.001) and then validated in the London
cohort (AUC: 0.83; 95% CI: 0.75 to 0.92; p < 0.001).
Scores of $2 and $3 points had high sensitivity
(93.6% and 72.3%), with adequate specificity
(52.1% and 83.6%) for the presence of AS-CA,
respectively (Figure 2). When excluding troponin,








































Lone AS - Medical
Lone AS - AVR
Aortic valve replacement (AVR) improved outcomes for both lone AS and dual pathology AS-CA. Post-AVR survival of AS-CA was comparable
to lone AS. Abbreviations as in Figure 2.
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135the AUC was 0.81 (95% CI: 0.73 to 0.88; p < 0.001)
(Supplemental Figure 1).
OUTCOME IN AS-CA VERSUS LONE AS. After a me-
dian of 1.7 years (IQR: 1.3 to 2.6 years), 97 (24%) of 407
patients referred for TAVR died. In this overall cohort,
there was a trend toward higher 1-year mortality in
patients with AS-CA versus patients with lone AS
(25.0% vs. 13.9%; log-rank p ¼ 0.05) (Figure 3). When
excluding the AL case, unadjusted all-cause mortality
of AS-CA was higher (196 deaths per 1,000 patient-
years) compared with lone AS (137 deaths per 1,000
patient years; p ¼ 0.001), with even those in grade 1
having significantly higher unadjusted all-cause
mortality than those with lone AS (p < 0.001). AVR
improved survival in patients with lone AS and AS-CA
compared with medical management (p < 0.001 and
0.003, respectively) (Figure 4). Results remained the
same when surgically managed patients were
excluded (p < 0.001 and 0.017, respectively)
(Supplemental Figure 2). There was a trend toward
higher levels of intervention in the lone AS cohort
(85.0% vs. 72.7% for lone AS vs. AS-CA; p ¼ 0.07).
Post-AVR, survival was comparable between lone AS
and AS-CA (log-rank; p ¼ 0.36). No interactionbetween CA and AVR was identified (p ¼ 0.94). One-
year mortality was 10.8 (AVR) versus 31.5% (medi-
cal) for the lone AS cohort and 16.2% versus 54.5% for
the AS-CA cohort; this persisted out to 2 years. ATTR-
targeting therapy (tafamidis only) was used in a mi-
nority of patients with AS-CA (all after AVR, 14.9%;
n ¼ 7 of 47) and was not associated with a mortality
difference (log-rank; p ¼ 0.40).
PREDICTORS OF OUTCOME. By multivariate Cox
regression analysis, AVR (HR: 0.62; 95% CI: 0.53 to
0.73; p < 0.001), serum albumin (HR: 0.70; 95% CI:
0.57 to 0.85; p ¼ 0.001), NT-proBNP (HR: 1.40;
95% CI: 1.12 to 1.76; p ¼ 0.003), creatinine (HR: 1.20;
95% CI: 1.04 to 1.38; p ¼ 0.015), and body mass index
(HR: 0.77; 95% CI: 0.61 to 0.97; p ¼ 0.018) were in-
dependent predictors of mortality for the overall
cohort (Table 3, Supplemental Table 1). In the inter-
vention subgroup, independent mortality predictors
were peri-procedural stroke (HR: 1.43; 95% CI: 1.25 to
1.63; p < 0.001), hematocrit (HR: 0.64; 95% CI: 0.48 to
0.84; p ¼ 0.001), serum albumin (HR: 0.73; 95% CI:
0.58 to 0.92; p ¼ 0.008), peak aortic jet velocity (HR:
0.73; 95% CI: 0.56 to 0.95; p ¼ 0.018), left atrial
diameter (HR: 1.34; 95% CI: 1.03 to 1.74; p ¼ 0.032),
TABLE 3 Multivariate Cox regression Analysis Assessing the Association of Parameters
With Mortality in the Overall Cohort
Baseline Clinical Parameters
Univariate Analysis Multivariate Analysis
HR (95% CI) p Value HR (95% CI) p Value
Aortic valve replacement 0.621 (0.5320.725) <0.001 0.617 (0.5260.723) <0.001
Albumin 0.605 (0.5510.804) <0.001 0.699 (0.5720.854) 0.001
NT-proBNP* 1.555 (1.2601.918) <0.001 1.401 (1.1181.755) 0.003
Creatinine 1.249 (1.0981.422) <0.001 1.196 (1.0351.383) 0.015
BMI 0.721 (0.5740.905) 0.005 0.765 (0.6130.965) 0.018
Troponin T 1.354 (1.2041.522) <0.001
Hematocrit 0.741 (0.6040.909) 0.004
Dual AS-CA 1.145 (0.9701.352) 0.100
AV-Vmax 0.673 (0.5510.823) <0.001
AV-MPG 0.666 (0.5320.834) 0.001
LVEF 0.825 (0.6840.995) 0.045
LVESV 1.270 (1.0771.498) 0.004
GLS 1.263 (1.0491.521) 0.014
Apical LS 1.260 (1.0541.505) 0.011
Mid-ventricular LS 1.237 (1.0301.486) 0.023
Bold values indicate statistical significance in multivariate testing. *NT-proBNP was graded into quartiles for this
analysis.
AS-CA ¼ dual aortic stenosis and cardiac amyloid pathology; CI ¼ confidence interval; HR ¼ hazard ratio; other
abbreviations as in Tables 1 and 2.
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136and body mass index (HR: 0.73; 95% CI: 0.54 to 0.98;
p ¼ 0.033) (Supplemental Table 2).
PERI-PROCEDURAL COMPLICATIONS. In patients
who underwent TAVR, major adverse events accord-
ing to Valve Academic Research Consortium-2
occurred at the same rate in those with lone AS and
AS-CA: stroke (2.7% vs. 2.9%); vascular complication
(4.7% vs. 2.9%); acute kidney injury (7.5% vs. 6.1%);
and pacemaker implantation (6.4% vs. 14.7%) (p for
all >0.05).
DISCUSSION
In this international multicenter study of older pa-
tients with severe AS referred for TAVR, we showed
that dual pathology of severe AS-CA conferred overall
worse disease by functional capacity, cardiac remod-
eling and biomarkers, and could be predicted by a
simple clinical score. Despite blinding clinicians
before heart team decisions, fewer patients with AS-
CA underwent TAVR and had overall worse out-
comes. However, if patients with AS-CA were selected
for and received TAVR, their outcomes were indis-
tinguishable from patients with lone AS. Medically
managed patients (both patients with lone AS or AS-
CA) had poor survival in line with previously pub-
lished data (e.g., PARTNER 1B trial [20]) (Central
Illustration). Therefore, we concluded that a diag-
nosis of AS-CA should not preclude patients from
TAVR.We also confirmed that AS-CA was common and
affected 1 in 8 patients referred for TAVR, either those
with amyloid deposition (grade 1) or those with clin-
ical amyloidosis (grade 2/3). The presence of occult
ATTR in AS was first described in patients who un-
derwent SAVR in 2016 (21). Since then, data from
multiple retrospective and prospective studies were
reported, (4–7,22,23), most of which were solely
dedicated to ATTR. This study added to the existing
data on the prevalence of AS-CA (4–7); data from our
study and other studies was 10 times higher than that
in unselected populations, in which prevalence in the
older adults was <1% in those aged 80 years or older
(24). CA in AS is predominantly of the ATTR-type, but
AL-amyloidosis needs to be excluded by concomitant
screening for plasma cell dyscrasia (25). Although
most of the patients with CA in the present series had
ATTR, 1 case of AL was identified. Although inter-
pretation of light-chain results is challenging and re-
quires multidisciplinary decision-making processes,
AL screening is essential in case of suspicion for CA,
because it usually requires urgent specific treatment
(26).
The perception of futility of aortic valve interven-
tion in AS-CA (27) originated from limited data in
small observational studies. In our data, we clearly
showed that TAVR improved outcome in patients
with AS-CA, and that on the basis of these data, TAVR
should not be withheld from patients with dual pa-
thology AS-CA. The clinical picture in AS-amyloidosis
(grade 2/3), with lower functional capacity, elevated
biomarkers, and impaired biventricular function,
highlighted a more decompensated clinical state that
would likely affect outcome; although in our cohort,
there was no statistical outcome difference in those
patients who underwent TAVR. Patients with AS-
amyloid (grade 1) also had worse outcomes, despite
only mild remodeling (with a lower SV index) and a
lower prevalence of electrical disturbances; there-
fore, AS-amyloid could not be considered as clinically
irrelevant or benign. Larger prospective studies and
registry data are warranted to understand the
importance of grade 1 AS-amyloid.
Routine screening of older adult patients with se-
vere AS or AS-CA using bone scintigraphy is not
feasible in routine clinical practice. However, patients
with AS-CA have distinct clinical risk profiles,
including older age, a history of carpal tunnel syn-
drome, elevated troponin levels, increased septal
thickness and E/A ratio on echocardiography, and
right bundle branch block and lower Sokolow criteria
on electrocardiography. Those parameters were in-
tegrated into a simple clinical scoring system that
helped to identify patients with AS with a high
CENTRAL ILLUSTRATION Concomitant Pathology Aortic Stenosis-Cardiac Amyloidosis
Nitsche, C. et al. J Am Coll Cardiol. 2021;77(2):128–39.
Concomitant pathology aortic stenosis-cardiac amyloidosis. PARTNER 1B data adapted from Kapadia et al. (20). AS ¼ aortic stenosis;
AVR ¼ aortic valve replacement; CA ¼ cardiac amyloidosis; DPD ¼ 99mtechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid;
RBBB ¼ right bundle branch block; TAVR ¼ transcatheter aortic valve replacement.
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137likelihood of coexisting CA and guide referral for bone
scintigraphy and exclusion of plasma cell dyscrasia.
We proposed a stepwise screening process for CA in
older adult patients with severe AS. The proposed
algorithm would allow high-volume TAVR centers to
detect CA with high sensitivity, without overstraining
local resources. Based on the data presented (see
Figure 2), scores of $2 points would instigate further
screening by bone scintigraphy and light-chain
assessment. TAVR should not be delayed for AS-CA
workup without evidence of plasma cell dyscrasia
because TAVR improves survival. An alternative
approach would be screening by obtaining the extra-
cellular volume fraction from pre-procedural TAVR
cardiac computed tomography (28); the use of routine
cardiac magnetic resonance is not feasible in all TAVR
patients.
Underlying pathophysiological aspects of AS-CA
are still incompletely understood. Despite thelimited data on amyloid prevalence in the aging
general population, ATTR has a lower prevalence in
noncardiac patients (<1%) and predominantly af-
fects older adult men (24). AS-CA appears to be
different, with not only a 10 times higher general
prevalence, but also near equal sex distribution and
predilection for grade 2/3 tracer uptake in AS (rather
than an equal distribution between grades). These
observations point toward a causal relationship be-
tween AS and amyloid. The increased LV afterload
posed by AS was hypothesized to prime the LV for
deposition of amyloid fibrils (6,29). This might be
driven by increased extracellular matrix turnover,
low grade inflammation, chronic subendocardial
ischemia, and resultant cell death because both
fibrosis and amyloid deposition occur with an
endocardial to epicardial gradient. In particular, the
significant shear stresses in AS could cause an
increased TTR deposition through a mechano-
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: Concomitant CA occurs in 1 of 8
patients with severe AS referred for TAVR and is
associated with more severe functional incapacity,
cardiac remodeling, and adverse prognosis. Following
TAVR, the outcomes of patients with concomitant CA
were not significantly different from those with AS
without CA.
TRANSLATIONAL OUTLOOK: Future studies
should determine whether ATTR-specific treatment
improves survival in patients with AS and ATTR-CA
following aortic valve replacement.
Nitsche et al. J A C C V O L . 7 7 , N O . 2 , 2 0 2 1
Outcome of Cardiac Amyloidosis and Aortic Stenosis J A N U A R Y 1 9 , 2 0 2 1 : 1 2 8 – 3 9
138enzymatic cleavage process (30). Valve intervention,
per se, might stabilize ATTR by reducing the shear
stresses and thereby the aforementioned mechano-
enzymatic cleavage process (30), like AVR im-
proves gastrointestinal bleeding in Heyde syndrome
by reducing activation of acquired type-2A von
Willebrand factor (31). Alternatively, common up-
stream pathways might affect both amyloidosis and
valve stenosis progression; for example, higher
levels of systemic inflammation might accelerate
aortic valve calcification and drive greater cardiac
deposition of amyloidogenic proteins (32). Further
research is warranted to strengthen our under-
standing of underlying mechanisms of AS-CA,
especially with respect to amenability to novel
TTR therapeutics. Whether patients with AS-CA
post-AVR (i.e., afterload is treated) will benefit
from novel therapies that stabilize the TTR tetramer
(tafamidis) (33) or reduce TTR serum levels (AG10,
inotersen, patisiran) (34–36) is unclear. In our study,
7 of 47 patients with ATTR-CA received tafamidis
after AVR (on a named patient program in Austria).
Survival of the 40 therapy-naïve patients with ATTR
was similar to lone AS and parallel to findings in
other studies (6,9). Multicenter registries (e.g., the
Aortic Stenosis & Amyloidosis Registry) and larger
studies of patients with CA post-AVR are required
to elucidate the benefit of ATTR therapy in this
patient cohort, ideally in a randomized controlled
trial (patients with AS were excluded from previous
randomized controlled trials in this area).
STUDY LIMITATIONS. Despite the recruitment of pa-
tients before heart team recommendations, there
might still be a selection bias of those patients who
were actually referred to recruiting centers. Blinding
pre-procedure was broken for 2 reasons: 7 patients
had plasma cell dyscrasia that necessitated unblind-
ing, as per protocol. Austrian and U.K. centers used
echocardiographic strain software from different
vendors, which might have affected comparability of
respective data. Dual pathology AS-CA is much rarer
in younger patients (21), and at middle age, would be
affected by a different valve etiology (likely bicuspid)
and amyloid type (AL or hereditary ATTR). These
were not investigated in the present study; therefore,
prognosis and management strategies were not
generalizable to this younger group. As opposed to
previous findings (7), relative apical sparing was more
pronounced in patients with AS-CA, whereas globalLS was comparable between groups. This should be
re-evaluated in future studies. Mitral annular S was
not available for the derivation cohort (Vienna);
therefore, respective data were not presented. Single-
photon emission computed tomography/computed
tomography was not performed in the Vienna cohort;
however, blinded core laboratory adjudication
ensured that the diagnosis was as accurate as
possible. Cause of mortality was not ascertained.
CONCLUSIONS
Dual pathology of AS-CA is common in older patients
with AS referred for possible TAVR. We presented a
simple clinical scoring system to help identify those
in whom bone scintigraphy is indicated. Patients with
AS-CA had worse functional capacity, cardiac
remodeling pre-procedure, and a trend toward worse
prognosis if not treated by TAVR. However, mortality
was the same if TAVR was performed. Based on these
data, TAVR should not be withheld in AS-CA.
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